As of November 6, 2026, Aclaris Therapeutics, Inc. is a publicly traded company (Nasdaq: ACRS); its largest reported holder is BML Investment Partners, L.P., with 9.9% on Schedule 13G/A of April 27, 2026, then Biosion, Inc. (9.4%) (Schedule 13G/A, April 27, 2026).
Is this your company?
About to sign with, pay or invest in Aclaris Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aclaris Therapeutics, Inc. a real, registered company?
- Aclaris Therapeutics, Inc. files with the SEC under CIK 1557746 (its SEC filings).
- Its shares are listed under the ticker ACRS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Wayne, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aclaris Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Frazier Life Sciences Public Fund, L.P. (filed 2026-09-21).
Who are Aclaris Therapeutics, Inc.'s owners and officers?
Aclaris Therapeutics, Inc.: incorporated in Delaware; business address in Wayne, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G, 2026-09-21).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-12-04)
- : Executive Officer, Director (Form D, 2024-12-04)
- : Executive Officer (Form D, 2024-12-04)
- : Executive Officer (Form D, 2024-12-04)
- : Executive Officer (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
- : Director (Form D, 2024-12-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-21 | Frazier Life Sciences Public Fund, L.P. | 5.4% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.1% |
| Schedule 13G/A, 2026-05-12 | Vivo Opportunity Fund Holdings, L.P. | 4.3% |
| Schedule 13G/A, 2026-04-27 | Bml Investment Partners, L.P. | 9.9% |
| Schedule 13G, 2026-04-07 | Ra Capital Management, L.P. | 6.3% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-17 | Deep Track Capital, LP | 7% |
| Schedule 13G/A, 2026-02-09 | Bml Investment Partners, L.P. | 11.9% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 6.2% |
| Schedule 13G/A, 2026-01-09 | Biosion, Inc. | 9.4% |
| Schedule 13G/A, 2025-11-13 | Adage Capital Management, L.P. | 4.87% |
| Schedule 13G, 2025-07-29 | The Vanguard Group | 6.15% |
Questions about who owns Aclaris Therapeutics, Inc.
Who owns Aclaris Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Aclaris Therapeutics, Inc.: Bml Investment Partners, L.P. (9.9%, Schedule 13G/A, filed 2026-04-27), Biosion, Inc. (9.4%, Schedule 13G/A, filed 2026-01-09), Ra Capital Management, L.P. (9.1%, Schedule 13G/A, filed 2026-08-14), Deep Track Capital, LP (7%, Schedule 13G, filed 2026-03-17) and Blackrock, Inc. (6.2%, Schedule 13G/A, filed 2026-01-21); 1 more is listed above.
Who are the largest shareholders of Aclaris Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aclaris Therapeutics, Inc. on this page are Bml Investment Partners, L.P. (9.9%), Biosion, Inc. (9.4%) and Ra Capital Management, L.P. (9.1%).
When did Bml Investment Partners, L.P. buy into Aclaris Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bml Investment Partners, L.P. on this page is the Schedule 13G/A, filed 2026-02-09, reporting 11.9%; its latest, Schedule 13G/A filed 2026-04-27, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aclaris Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aclaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aclaris Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Aclaris Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 13,950,000 shares (8.8% of shares outstanding), held indirectly through Holdings of BML Investment Partners, L.P. (Form 4, 2026-04-27).
- , the chief executive and a director: 1,543,886 shares (0.97% of shares outstanding) (Form 4, 2026-02-05).
- , a director: 726,403 shares (0.46% of shares outstanding) (Form 4, 2026-06-08).
- , a director: 459,995 shares (0.29% of shares outstanding), 25,540 held directly and 434,455 indirectly (Form 4, 2026-06-08).
- , the chief scientific officer: 265,855 shares (0.17% of shares outstanding), 265,662 held directly and 193 indirectly (Form 4, 2025-03-04).
Shares outstanding: 158,612,149 as of 2026-10-30, from the company's latest SEC cover page.
How much has Aclaris Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-12-04 | $80M | $80M |
Keep reading
More on Aclaris Therapeutics, Inc. and the records around it.
Aclaris Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
Companies that share a holder
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Connect Biopharma Holdings Ltd (Oct 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), Allogene Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aclaris-therapeutics